Business Wire

AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial

Share

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was treated in the HEAL-IST™ trial (NCT 05280093). The first patient was treated by Drs. Mark LaMeir and Carlo de Asmundis at University Hospital Brussels. The HEAL-IST trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy™ Clamp for the treatment of drug-refractory patients diagnosed with Inappropriate Sinus Tachycardia (IST). Sinus tachycardia normally occurs when the body sends out signals to make the heart beat faster, such as when some people experience stress or physical exertion during exercise. When it happens unexpectedly or for no easily identifiable reason, the condition is called Inappropriate Sinus Tachycardia.

The HEAL-IST trial is a prospective, multicenter, single-arm study of 142 patients at up to 40 centers in the United States and Europe. The therapy being studied involves a hybrid epicardial and endocardial procedure, during which a cardiac surgeon and an electrophysiologist work together to create lesions on the right side of the heart. The primary effectiveness endpoint is freedom from IST, defined as having a mean heart rate of less than 90 beats per minute, or at least a 15% reduction in mean heart rate compared to a pre-operative baseline. The primary safety endpoint is procedure or device related adverse events through 30 days after the surgery is completed.

“Symptomatic IST is a serious arrhythmia that dramatically decreases the quality of life in predominantly younger adults, and more specifically, young women,” said Dr. LaMeir, Professor and Head of Cardiac Surgery at University Hospital Brussels, and co-principal investigator in the HEAL-IST trial. “Further, since current antiarrhythmic drug treatment has limited long-term effect, and societal guidelines do not advise sinus node ablation or modulation, this landmark study of sinus node sparing hybrid ablation has the potential to establish a standard of care for these patients.”

“We believe that cardiac surgeons and electrophysiologists working together is a safe and highly effective way to treat complex arrhythmias,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “The HEAL-IST trial is an example of AtriCure’s commitment to, and leadership in improving the lives of patients. The therapy has the potential to significantly expand our addressable markets.”

“IST is a common disease that is often under or mis-diagnosed,” said Dr. de Asmundis, Professor and Director of Heart Rhythm Management at University Hospital Brussels, and co-principal investigator in the trial. “There are currently no approved treatments for this disease. The HEAL-IST trial, which is based on years of research from our clinic, has a chance to prove how successful this procedure can be.”

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Angie Wirick
Investor Relations
Chief Financial Officer
(513) 755-5334
awirick@atricure.com

Valerie Storch-Willhaus
Media Relations
Vice President, Corporate Marketing & Communications
(612) 605-3311
vstorch-willhaus@atricure.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ganymed Robotics Raises €21M to Complete the Development of Its Next Generation Surgical Robot and Prepare for a Commercial Launch7.7.2022 09:00:00 EEST | Press release

Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, announced it has raised €21 million in the oversubscribed first close of its Series B funding. The round was led by Cathay Health, with participation of Credit Mutuel Innovation, Kurma Partners, BNP Paribas Développement and internationally renowned surgeons. The funding will be used to: - Support Ganymed’s expansion in France and in the United States; - Finalize the industrial development of its surgical robotic assistant for knee arthroplasty (TKA); - Accelerate regulatory and marketing developments across geographies; - Diversify the innovation product pipeline. Since inception in 2018, Ganymed Robotics has experienced a rapid growth. In collaboration with world-class clinicians, it has validated its proprietary algorithms and collected unique in vivo data via a 100-patient observational study, successfully completed functional prototype tests, initiated industrialization of

The Solidarity Transport Hub Company Starts Looking for a Financial Investor7.7.2022 09:00:00 EEST | Press release

The Solidarity Transport Hub company from Poland is starting the process of selecting a Financial Partner experienced in investments in the infrastructure industry to run a joint venture in the form of a special purpose vehicle subsidiary of the STH ("Airport Component SPV"). The company is waiting for applications from interested contractors until August the 26th 2022. Solidarity Transport Hub (STH) is the largest infrastructure investment in Poland, which consists of constructing the largest airport in the Central Europe region as well as developing ca. 2000 km of new railways countrywide. STH`s projects are financed from three sources: treasury securities, commercial financing, and funds from the European Union. – From the very beginning, we were prepared to propose cooperation to potential investors. We are a reliable and attractive partner for foreign investors in the wake of the need to build a large airport, which will become the main transfer hub in our part of Europe – says Mi

ADVA Optical Networking SE: ADVA Optical Networking SE to enter into negotiations for a domination agreement or domination and profit and loss transfer agreement with Acorn HoldCo, Inc.7.7.2022 01:15:00 EEST | Press release

Today, Acorn HoldCo, Inc. (“Acorn HoldCo”) has informed ADVA Optical Networking SE (“ADVA”) about its intention to enter into negotiations regarding the conclusion of a domination agreement (“DA”) or a domination and profit and loss transfer agreement (“DPLTA”, either the DA or the DPLTA the “Agreement”) within the meaning of Sec. 291 para. 1 of the German Stock Corporation Act (Aktiengesetz) with Acorn HoldCo (or a subsidiary yet to be established) as the dominating entity and ADVA as the dominated entity. ADVA’s management board has decided to enter into negotiations for such an Agreement. The necessary preparatory measures include obtaining a valuation memorandum and proposing a contract auditor to be appointed by the court. The decision for or against the conclusion of an Agreement will be taken at a later date following a comprehensive review in consultation and coordination with Acorn HoldCo’s management. To be effective, an Agreement will require the approval of ADVA’s general m

ADVA CEO Brian Protiva to step down, CTO Christoph Glingener appointed as successor6.7.2022 23:45:00 EEST | Press release

ADVA (FSE: ADV) today announced that Brian Protiva is to step down as CEO. After a transition period of several weeks, Protiva will assume the role of vice chairman of Acorn HoldCo, Inc. (the holding company of Adtran and ADVA). Christoph Glingener will be appointed ADVA’s new CEO and will also continue as the company’s CTO. During Protiva’s 25-year tenure as chief executive officer, he successfully steered the company from a small start-up to an industry leader in metro WDM and Ethernet access devices. As ADVA is about to complete its business combination with Adtran, Protiva will support the further unification of the companies over the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005829/en/ Brian Protiva, CEO, ADVA (Photo: Business Wire) “Working side-by-side with Brian for eight years, I was privileged to see one of the industry‘s true leaders develop a world-class company. During his 25 years as A

MSCI Schedules Earnings Call to Review Second Quarter 2022 Results6.7.2022 21:30:00 EEST | Press release

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today it will release its results for the second quarter 2022 on Tuesday, July 26, 2022, before the market opens. A copy of the earnings release, as well as an earnings presentation and a quarterly update, will be made available on MSCI's Investor Relations website. MSCI's senior management will review the second quarter 2022 results on Tuesday, July 26, 2022 at 11:00 AM Eastern Time. To listen to the live event via webcast, visit the events and presentations section of MSCI's Investor Relations website, https://ir.msci.com/events-and-presentations or to join via telephone, please register yourself at https://ir.msci.com/events-and-presentations. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including a dial-in number and a unique participant pin that can be used to access the c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom